Tumor microenvironment is not an ‘innocent bystander’ in the resistance to treatment of head and neck cancers (Review)
- Authors:
- Laura Mazilu
- Andra-Iulia Suceveanu
- Dana-Lucia Stanculeanu
- Andreea-Daniela Gheorghe
- Gabriela Fricatel
- Serban-Mircea Negru
-
Affiliations: Department of Oncology, ‘Ovidius’ University, 900527 Constanţa, Romania, Department of Gastroenterology, ‘Ovidius’ University, 900527 Constanţa, Romania, Department of Oncology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Oncology, ‘Victor Babes’ University of Medicine and Pharmacy, 300041 Timisoara, Romania - Published online on: August 5, 2021 https://doi.org/10.3892/etm.2021.10562
- Article Number: 1128
This article is mentioned in:
Abstract
|
Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ghantous Y and Abu Elnaaj I: Global incidence and risk factors of oral cancer. Harefuah. 156:645–649. 2017.PubMed/NCBI | |
|
Haddad RI and Shin DM: Recent advances in head and neck cancer. N Engl J Med. 359:1143–1154. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Bhat AA, Yousuf P, Wani NA, Rizwan A, Chauhan S, Siddiqi MA, Bedognetti D, El-Rifai W, Frenneaux MP, Batraet SK, et al: Tumor microenvironment: An evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. Signal Transduct Target Ther. 6(12)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang HC, Chan LP and Cho SF: Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma. Front Oncol. 9(1084)2019.PubMed/NCBI View Article : Google Scholar | |
|
Solomon I, Voiculescu VM, Caruntu C, Lupu M, Popa A, Ilie MA, Albulescu R, Caruntu A, Tanase C, Constantin C, et al: Neuroendocrine factors and head and neck squamous cell carcinoma: An affair to remember. Dis Markers. 2018(9787831)2018.PubMed/NCBI View Article : Google Scholar | |
|
Hsu WL, Yu KJ, Chiang CJ, Chen TC and Wang CP: Head and neck cancer incidence trends in Taiwan, 1980-2014. Int J Head Neck Sci. 1:180–189. 2017. | |
|
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 29:4294–4301. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, et al: Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 18:541–550. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Maier H, Dietz A, Gewelke U, Heller WD and Weidauer H: Tobacco and alcohol and the risk of head and neck cancer. Clin Investig. 70:320–327. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Sturgis EM and Wei Q: Genetic susceptibility-molecular epidemiology of head and neck cancer. Curr Opin Oncol. 14:310–317. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Preston-Martin S, Thomas DC, White SC and Cohen D: Prior exposure to medical and dental x-rays related to tumors of the parotid gland. J Natl Cancer Inst. 80:943–949. 1988.PubMed/NCBI View Article : Google Scholar | |
|
Boffetta P, Richiardi L, Berrino F, Estève J, Pisani P, Crosignani P, Raymond L, Zubiri L, Del Moral A, Lehmannet W, et al: Occupation and larynx and hypopharynx cancer: An international case-control study in France, Italy, Spain, and Switzerland. Cancer Causes Control. 14:203–212. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ and Yanget CS: Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 345:1877–1882. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Kobayashi I, Shima K, Saito I, Kiyoshima T, Matsuo K, Ozeki S, Ohishi M and Sakai H: Prevalence of Epstein-Barr virus in oral squamous cell carcinoma. J Pathol. 189(34)1999.PubMed/NCBI View Article : Google Scholar | |
|
Mahale P, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ and Torres HA: Association between hepatitis C virus and head and neck cancers. J Natl Cancer Inst. 108(djw035)2016.PubMed/NCBI View Article : Google Scholar | |
|
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al: Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 34:3838–3845. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ferris RL, Blumenschein GR, Fayette J, Guigay J, Colevas AD, Licitra LF, Harrington KJ, Kasper S, Vokes EE, Even C, et al: Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Check Mate 141. Am Soc Clin Oncol. 34 (Suppl 15)(S6009)2016. | |
|
Wu T and Dai Y: Tumor microenvironment and therapeutic response. Cancer Lett. 387:61–68. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Soysal SD, Tzankov A and Muenst SE: Role of the tumor microenvironment in breast cancer. Pathobiology. 82:142–152. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Denton AE, Roberts EW and Fearon DT: Stromal cells in the tumor microenvironment. Adv Exp Med Biol. 1060:99–114. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Peltanova B, Raudenska M and Masarik M: Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: A systematic review. Mol Cancer. 18(63)2019.PubMed/NCBI View Article : Google Scholar | |
|
Giancotti FG: Deregulation of cell signaling in cancer. FEBS Lett. 588:2558–2570. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Arneth B: Tumor microenvironment. Medicina (Kaunas). 56(15)2019.PubMed/NCBI View Article : Google Scholar | |
|
Ludwig S, Sharma P, Theodoraki MN, Pietrowska M, Yerneni SS, Lang S, Ferrone S and Whitesideet TL: Molecular and functional profiles of exosomes from HPV (+) and HPV (-) head and neck cancer cell lines. Front Oncol. 8(445)2018.PubMed/NCBI View Article : Google Scholar | |
|
Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, et al: Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 21:870–881. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Cristina V, Herrera-Gómez RG, Szturz P, Espeli V and Siano M: Immunotherapies and future combination strategies for head and neck squamous cell carcinoma. Int J Mol Sci. 20(5399)2019.PubMed/NCBI View Article : Google Scholar | |
|
Chaudhary S, Ganguly K, Muniyan S, Pothuraju R, Sayed Z, Jones DT, Batra SK and Macha MA: Immunometabolic alterations by HPV infection: New dimensions to head and neck cancer disparity. J Natl Cancer Inst. 111:233–244. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Quezada SA, Peggs KS, Simpson TR and Allison JP: Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication. Immunol Rev. 241:104–118. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Dobrenis K, Gauthier LR, Barroca V and Magnon C: Granulocyte colony-stimulating factor off-target effect on nerve outgrowth promotes prostate cancer development. Int J Cancer. 136:982–988. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hu P, Wang G, Shen M, Zhang P, Zhang J, Du J and Liu Q: Intratumoral polymorphonuclear granulocyte is associated with poor prognosis in squamous esophageal cancer by promoting epithelial-mesenchymal transition. Future Oncol. 11:771–783. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Fang J, Li X, Ma D, Liu X, Chen Y, Wang Y, Yan Lui VW, Xia J, Cheng B and Wang Z: Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC Cancer. 17(375)2017.PubMed/NCBI View Article : Google Scholar | |
|
Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL and Furuya N: Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 55:151–159. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Whiteside TL: Immunobiology of head and neck cancer. Cancer Metastasis Rev. 24:95–105. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darraghet L, et al: Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration. Clin Cancer Res. 24:5368–5380. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Echarri M, Lopez-Martin A and Hitt R: Targeted therapy in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma (LA-R/M HNSCC). Cancers (Basel). 8(27)2016.PubMed/NCBI View Article : Google Scholar | |
|
Kather JN, Suarez-Carmona M, Charoentong P, Weis CA, Hirsch D, Bankhead P, Horning M, Ferber D, Kel I, Herpel E, et al: Topography of cancer-associated immune cells in human solid tumors. Elife. 7(e36967)2018.PubMed/NCBI View Article : Google Scholar | |
|
Johnson SD, De Costa AM and Young MR: Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer. Cancers (Basel). 6:756–770. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Bonomi M, Patsias A, Posner M and Sikora A: The role of inflammation in head and neck cancer. Adv Exp Med Biol. 816:107–127. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE, Voiculescu V, et al: Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol. 52:637–655. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Carpén T, Sjöblom A, Lundberg M, Haglund C, Markkola A, Syrjänen S, Tarkkanen J, Mäkitie A, Hagström J and Mattila P: Presenting symptoms and clinical findings in HPV-positive and HPV-negative oropharyngeal cancer patients. Acta Otolaryngol. 138:513–518. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Panwar A, Batra R, Lydiatt WM and Ganti AK: Human papilloma virus positive oropharyngeal squamous cell carcinoma: A growing epidemic. Cancer Treat Rev. 40:215–219. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Pytynia KB, Dahlstrom KR and Sturgis EM: Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 50:380–386. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 517:576–582. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, et al: Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 21:632–641. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimmet DL, et al: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 24:736–747. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee K-W, Ganly I, Hakimi AA, Chan TA and Morris LG: The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 1(e89829)2016.PubMed/NCBI View Article : Google Scholar | |
|
Koneva LA, Zhang Y, Virani S, Hall PB, McHugh JB, Chepeha DB, Wolf GT, Carey TE, Rozek LS and Sartor MA: HPV integration in HNSCC correlates with survival outcomes, immune response signatures, and candidate drivers. Mol Cancer Res. 16:90–102. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Kindt N, Descamps G, Seminerio I, Bellier J, Lechien JR, Mat Q, Pottier C, Delvenne P, Journé F and Saussez S: High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma. Oral Oncol. 67:183–191. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Seminerio I, Descamps G, Dupont S, de Marrez L, Laigle JA, Lechien JJ, Kindt N, Journe F and Saussez S: Infiltration of FoxP3+ regulatory T cells is a strong and independent prognostic factor in head and neck squamous cell carcinoma. Cancers (Basel). 11(227)2019.PubMed/NCBI View Article : Google Scholar | |
|
Punt S, Dronkers EA, Welters MJ, Goedemans R, Koljenović S, Bloemena E, Snijders PJ, Gorter A, van der Burg SH, Baatenburg de Jong RJ and Jordanova ES: A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol Immunother. 65:393–403. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Oguejiofor K, Hall J, Slater C, Betts G, Hall G, Slevin N, Dovedi S, Stern PL and Westet CM: Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. Br J Cancer. 113:886–893. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lechien JR, Descamps G, Seminerio I, Furgiuele S, Dequanter D, Mouawad F, Badoual C, Journe F and Saussez S: HPV Involvement in the tumor microenvironment and immune treatment in head and neck squamous cell carcinomas. Cancers. 12(1060)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wolf GT, Chepeha DB, Bellile E, Nguyen A, Thomas D and McHugh J: Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: A preliminary study. Oral Oncol. 51:90–95. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Seminerio I, Kindt N, Descamps G, Bellier J, Lechien JR, Mat Q, Pottier C, Journé F and Saussez S: High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus. Oncotarget. 9:11046–11059. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Wagner S, Wittekindt C, Reuschenbach M, Hennig B, Thevarajah M, Würdemann N, Prigge ES, von Knebel Doeberitz M, Dreyer T, Gattenlöhneret S, et al: CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma. Int J Cancer. 138:2263–2273. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Guess JC and McCance DJ: Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol. 79:14852–14862. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Kindt N, Descamps G, Seminerio I, Bellier J, Lechien JR, Pottier C, Larsimont D, Journé F, Delvenne P and Saussez S: Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas. Oral Oncol. 62:1–10. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Matthews K, Leong CM, Baxter L, Inglis E, Yun K, Bäckström T, Doorbar J and Hibma M: Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol. 77:8378–8385. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Kanodia S, Fahey LM and Kast WM: Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 7:79–89. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Wellenstein MD and de Visser KE: Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity. 48:399–416. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Outh-Gauer S, Morini A, Tartour E, Lépine C, Jung AC and Badoual C: The microenvironment of head and neck cancers: Papillomavirus involvement and potential impact of immunomodulatory treatments. Head Neck Pathol. 14:330–340. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zimmermann M, Zouhair A, Azria D and Ozsahin M: The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications. Radiat Oncol. 1(11)2006.PubMed/NCBI View Article : Google Scholar | |
|
Hernandez CP, Morrow K, Velasco C, Wyczechowska DD, Naura AS and Rodriguez PC: Effects of cigarette smoke extract on primary activated T cells. Cell Immunol. 282:38–43. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Desrichard A, Kuo F, Chowell D, Lee KW, Riaz N, Wong RJ, Chan TA and Morris L: Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas. J Natl Cancer Inst. 110:1386–1392. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, et al: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 12:5064–5073. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al: Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 7(10501)2016.PubMed/NCBI View Article : Google Scholar | |
|
Jenkins RW, Barbie DA and Flaherty KT: Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 118:9–16. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al: Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6:202–216. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 375:819–829. 2016.PubMed/NCBI View Article : Google Scholar | |
|
O'Donnell JS, Long GV, Scolyer RA, Teng MW and Smyth MJ: Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 52:71–81. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Vargas FA, Furness AJ, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Rota EM, Dahan R, Georgiou A, Sledzinska A, et al: Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity. 46:577–586. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishopet JA, et al: Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 73:1733–1741. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Wan Y, Vagenas D, Salazar C, Kenny L, Perry C, Calvopiña D and Punyadeera C: Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients. Oncotarget. 8:99990–100001. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Vahabi M, Pulito C, Sacconi A, Donzelli S, D'Andrea M, Manciocco V, Pellini R, Paci P, Sanguineti G, Strigariet L, et al: miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. J Exp Clin Cancer Res. 38(141)2019.PubMed/NCBI View Article : Google Scholar | |
|
Meulendijks D, Tomasoa NB, Dewit L, Smits PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH, Schellens JHM and Cats A: HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer. 112:1358–1366. 2015.PubMed/NCBI View Article : Google Scholar | |
|
O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, et al: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 31:543–550. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Baruah P, Bullenkamp J, Wilson P, Lee M, Kaski JC and Dumitriu IE: TLR9 mediated tumor-stroma interactions in human papilloma virus (HPV)-positive head and neck squamous cell carcinoma up-regulate PD-L1 and PD-L2. Front Immunol. 10(1644)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Janget RW, et al: Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with >25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 107:142–152. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375:1856–1867. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD, et al: Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: A phase IB study. J Clin Oncol. 38:2427–2437. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudevaet L, et al: Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 31:942–950. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, et al: Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-Low/Negative recurrent or metastatic HNSCC: The phase 2 CONDOR randomized clinical trial. JAMA Oncol. 5:195–203. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tsuchikawa T, Miyamoto M, Yamamura Y, Shichinohe T, Hirano S and Kondo S: The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surgical Oncol. 19:1713–1719. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Bracci L, Schiavoni G, Sistigu A and Belardelli F: Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21:15–25. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Concu R and Cordeiro M: Cetuximab and the head and neck squamous cell cancer. Curr Top Medicinal Chem. 18:192–198. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland A, et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Şimşek H, Han Ü, Önal B and Şimişek G: The expression of EGFR, cerbB2, p16, and p53 and their relationship with conventional parameters in squamous cell carcinoma of the larynx. Turkish J Med Sci. 44:411–416. 2014.PubMed/NCBI | |
|
Liang K, Ang KK, Milas L, Hunter N and Fan Z: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 57:246–254. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Young RJ, Rischin D, Fisher R, McArthur GA, Fox SB, Peters LJ, Corry J, Lim A, Waldeck K and Solomon B: Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 20:1230–1237. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknoset TN, et al: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 26:3128–3137. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Bernier J, Bentzen SM and Vermorken JB: Molecular therapy in head and neck oncology. Nat Rev Clin Oncol. 6:266–277. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Henderson S, Chakravarthy A, Su X, Boshoff C and Fenton TR: APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7:1833–1841. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 377:2500–2501. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhynet M, et al: Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 362(eaar3593)2018.PubMed/NCBI View Article : Google Scholar | |
|
Li W, Wildsmith S, Ye J, Si H, Morsli N, He P, Shetty J, Yovine AJ, Holoweckyj N, Raja R, et al: Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure. J Clin Oncol. 38(6511)2020. | |
|
Hladikova K, Koucky V, Boucek J, Laco J, Grega M, Hodek M, Zabrodsky M, Vosmik M, Rozkosova K, Vosmikova H, et al: Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J Immunother Cancer. 7(26)2019.PubMed/NCBI View Article : Google Scholar | |
|
Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA and Capone M: Immunoscore and immunoprofiling in cancer: An update from the melanoma and immunotherapy bridge 2015. J Transl Med. 14(273)2016.PubMed/NCBI View Article : Google Scholar | |
|
Zhang XM, Song LJ, Shen J, Yue H, Han YQ, Yang CL, Liu SY, Deng JW, Jiang Y, Fu GH and Shen WW: Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma. Hum Pathol. 82:104–112. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Jamieson NB and Maker AV: Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther. 24:134–140. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Prat A, Navarro A, Pare L, Reguart N, Galvan P, Pascual T, Martinez A, Nuciforo P, Comerma L, Alos L, et al: Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77:3540–3550. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Luchini C, Bibeau F, Ligtenberg MJ, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, et al: ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann Oncol. 30:1232–1243. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Roy S and Trinchieri G: Microbiota: A key orchestrator of cancer therapy. Nat Rev Cancer. 17:271–285. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Greenhill C: Gut microbiota: Anti-cancer therapies affected by gut microbiota. Nat Rev Gastroenterol Hepatol. 11(1)2014.PubMed/NCBI View Article : Google Scholar | |
|
Brandi G and Frega G: Microbiota: Overview and implication in immunotherapy-based cancer treatments. Int J Mol Sci. 20(2699)2019.PubMed/NCBI View Article : Google Scholar |
